Alpha Tau Treats First Pancreatic Cancer Patient in Italy, Expands Delivery Options for Alpha DaRT® Therapy

summarizeSummary

Alpha Tau Medical announced the successful treatment of the first pancreatic cancer patient in Italy with its Alpha DaRT® therapy, introducing a new dual delivery method that expands treatment accessibility.

check_boxKey Events

• First Patient Treated in Italy

  Alpha Tau successfully treated the first pancreatic cancer patient in Italy with its Alpha DaRT® therapy at the University of Verona's Pancreas Institute, as part of a new feasibility and safety study (CTP-PANC-03).

• New Dual Delivery Method Introduced

  The study is the first Alpha DaRT pancreatic cancer protocol worldwide to permit both endoscopic ultrasound (EUS)-guided and percutaneous delivery of Alpha DaRT sources, significantly expanding access alternatives for physicians.

• Global Clinical Expansion

  This treatment follows the first European patient treated in France in April 2026 and joins the ongoing IMPACT multicenter trial in the United States, reflecting the rapid global expansion of Alpha Tau's pancreatic cancer program.

auto_awesomeAnalysis

This filing marks a significant clinical milestone for Alpha Tau Medical, announcing the successful treatment of the first pancreatic cancer patient in Italy using its Alpha DaRT® therapy. Crucially, this study introduces a new dual delivery method, allowing for both endoscopic ultrasound (EUS)-guided and percutaneous placement of the Alpha DaRT sources. This expansion of delivery options is vital as it broadens the accessibility of the treatment to a wider range of patients and medical specialists, potentially accelerating adoption and market penetration. Pancreatic cancer remains one of the most lethal malignancies globally, with a particularly grim outlook in Italy, underscoring the high unmet medical need this therapy aims to address. This development reinforces the company's global clinical expansion strategy for its pancreatic cancer program, following recent positive data and ongoing trials in France and the United States.